FluigeniX

FluigeniX is developing a cutting-edge microfluidic technology that provides the hematologist with better decision support in personalizing therapies to CLL and Multiple Myeloma patients. After a decade of hard work and dedication, our scientific team headed by PROF. DORON GERBER from the Faculty of Life-Sciences in BAR-ILAN UNIVERSITY has achieved a significant breakthrough that can redefine the world of personalized medicine. Our microfluidic based device is using blood samples to predict cancer patient response to multiple therapies, combinations and drug cocktails. This proprietary platform allows us to fit each patient with the optimal treatment for him.